Literature DB >> 33807704

Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata.

Reiko Kageyama1, Taisuke Ito1, Shiho Hanai2, Naomi Morishita1, Shinsuke Nakazawa1, Toshiharu Fujiyama1, Tetsuya Honda1, Yoshiki Tokura3.   

Abstract

Alopecia areata (AA) is regarded as a tissue-specific and cell-mediated autoimmune disorder. Regarding the cytokine balance, AA has been considered a type 1 inflammatory disease. On the other hand, AA often complicates atopic dermatitis (AD) and AD is regarded as type 2 inflammatory disease. However, the immunological aspects of AA in relation to AD are still poorly understood. Therefore, we aim to clarify the immunological properties of AD-associated AA. In this study, we performed comparative analysis of the expression of intracytoplasmic cytokines (IFN-γ, IL-4, and IL-13), chemokine receptors (CXCR3 and CCR4) in peripheral blood which were taken from healthy controls, non-atopic AA patients, AA patients with extrinsic AD, and AA patients with intrinsic AD by flowcytometric analysis. We also compared the scalp skin samples taken from AA patients with extrinsic AD before and after treatment with dupilumab. In non-atopic AA patients, the ratios of CD4+IFN-γ+ cells to CD4+IL-4+ cells and CD4+IFN-γ+ cells to CD4+IL-13+ cells were higher than those in AA patients with extrinsic AD. Meanwhile, the ratio of CD8+IFN-γ+ cells to CD8+IL-13+ cells was significantly higher in the non-atopic AA than in the healthy controls. In AA patients with extrinsic AD, the skin AA lesion showed dense infiltration of not only CXCR3+ cells but also CCR4+ cells around hair bulb before dupilumab treatment. However, after the treatment, the number of CXCR3+ cells had no remarkable change while the number of CCR4+ cells significantly decreased. These results indicate that the immunological condition of AA may be different between atopic and non-atopic patients and between extrinsic and intrinsic AD patients. Our study provides an important notion that type 2 immunity may participate in the development of AA in extrinsic AD patients. It may be considered that the immunological state of non-atopic AA is different from that of atopic AA.

Entities:  

Keywords:  IFN-γ; IL-13; alopecia areata; extrinsic atopic dermatitis; intrinsic atopic dermatitis

Mesh:

Substances:

Year:  2021        PMID: 33807704      PMCID: PMC7961331          DOI: 10.3390/ijms22052618

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  50 in total

1.  Alopecia areata induced in C3H/HeJ mice by interferon-gamma: evidence for loss of immune privilege.

Authors:  Amos Gilhar; Yossi Kam; Bedia Assy; Richard S Kalish
Journal:  J Invest Dermatol       Date:  2005-01       Impact factor: 8.551

2.  Dupilumab and Alopecia: Causative or Therapeutic?

Authors:  Aleksi J Hendricks; Peter A Lio; Vivian Yan Shi
Journal:  Dermatology       Date:  2019-04-18       Impact factor: 5.366

3.  Alopecia Universalis and Atopic Dermatitis Improvement with Dupilumab: Demonstration of a Shared Pathophysiology and Clinical Efficacy.

Authors:  Hershel Dobkin; Renata Mullen; Matthew Zirwas
Journal:  Skinmed       Date:  2019-05-29

4.  Interferon-gamma-deficient mice are resistant to the development of alopecia areata.

Authors:  P Freyschmidt-Paul; K J McElwee; R Hoffmann; J P Sundberg; M Vitacolonna; S Kissling; M Zöller
Journal:  Br J Dermatol       Date:  2006-09       Impact factor: 9.302

Review 5.  What's new in the treatment of atopic dermatitis?

Authors:  Annunziata Dattola; Luigi Bennardo; Martina Silvestri; Steven Paul Nisticò
Journal:  Dermatol Ther       Date:  2018-12-12       Impact factor: 2.851

6.  'Follicular Swiss cheese' pattern--another histopathologic clue to alopecia areata.

Authors:  Cornelia S L Müller; Laila El Shabrawi-Caelen
Journal:  J Cutan Pathol       Date:  2010-11-10       Impact factor: 1.587

7.  Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.

Authors:  Solam Lee; Beom Jun Kim; Young Bin Lee; Won-Soo Lee
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

Review 8.  What causes alopecia areata?

Authors:  K J McElwee; A Gilhar; D J Tobin; Y Ramot; J P Sundberg; M Nakamura; M Bertolini; S Inui; Y Tokura; L E King; B Duque-Estrada; A Tosti; A Keren; S Itami; Y Shoenfeld; A Zlotogorski; R Paus
Journal:  Exp Dermatol       Date:  2013-09       Impact factor: 3.960

Review 9.  New and Emerging Therapies for Alopecia Areata.

Authors:  Aunna Pourang; Natasha Atanaskova Mesinkovska
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

10.  Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis.

Authors:  Dema T Alniemi; Laura McGevna
Journal:  JAAD Case Rep       Date:  2019-01-11
View more
  2 in total

1.  Dupilumab for the treatment of alopecia areata in children with atopic dermatitis.

Authors:  Sung Kyung Cho; Brittany G Craiglow
Journal:  JAAD Case Rep       Date:  2021-07-27

Review 2.  The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications.

Authors:  Anna Waśkiel-Burnat; Marta Osińska; Anna Salińska; Leszek Blicharz; Mohamad Goldust; Małgorzata Olszewska; Lidia Rudnicka
Journal:  Cells       Date:  2021-12-02       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.